These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15649923)

  • 1. Agencies "failed miserably" over COX-2 inhibitor.
    Kermode-Scott B
    BMJ; 2005 Jan; 330(7483):113. PubMed ID: 15649923
    [No Abstract]   [Full Text] [Related]  

  • 2. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 3. The Vioxx debacle revisited.
    Mohapatra PR; Janmeja AK
    Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
    [No Abstract]   [Full Text] [Related]  

  • 4. Under surveillance.
    Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
    [No Abstract]   [Full Text] [Related]  

  • 5. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS
    N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract]   [Full Text] [Related]  

  • 6. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 7. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 8. COX-2 inhibitors--lessons in drug safety.
    Psaty BM; Furberg CD
    N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
    [No Abstract]   [Full Text] [Related]  

  • 9. What ails the FDA?
    Cohen FJ
    N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962406
    [No Abstract]   [Full Text] [Related]  

  • 10. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 11. Discontinuation of Vioxx.
    Garattini S; Bertelé V
    Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
    [No Abstract]   [Full Text] [Related]  

  • 12. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 13. What ails the FDA?
    Gorelick KJ
    N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814
    [No Abstract]   [Full Text] [Related]  

  • 14. Will Merck survive Vioxx?
    Simons J; Stipp D
    Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
    [No Abstract]   [Full Text] [Related]  

  • 15. What is a 'safe' drug?
    Healy B
    US News World Rep; 2004 Dec; 137(21):37. PubMed ID: 15636504
    [No Abstract]   [Full Text] [Related]  

  • 16. Vioxx, the implosion of Merck, and aftershocks at the FDA.
    Horton R
    Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041
    [No Abstract]   [Full Text] [Related]  

  • 17. Europe also needs agency for postmarketing surveillance.
    Garattini S
    BMJ; 2005 Mar; 330(7490):540. PubMed ID: 15746147
    [No Abstract]   [Full Text] [Related]  

  • 18. [Funtional phase IV?].
    Heinzl S
    Med Monatsschr Pharm; 2005 Jan; 28(1):1. PubMed ID: 15693597
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety, scrutiny and conflicts: assessing the fallout and lessons learned from pharmaceuticals.
    Lanzafame RJ
    Photomed Laser Surg; 2005 Feb; 23(1):1-2. PubMed ID: 15782023
    [No Abstract]   [Full Text] [Related]  

  • 20. The pain game.
    Wadman M
    Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.